Few studies have explored the levels of LFABP in chronic liver disease.14,15 However, to our knowledge, this is the first study to enroll patients with CHB and compare LFABP levels in CHB, CHC, and NAFLD patients with the findings of histological examination. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.